Systemic Therapy for chordoma publications
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGH
1
EvidenceTherapeutic ClassDrug NameBrand NameTargetPatientsResultsReference
2
Phase II Trial
Immune Checkpoint Inhibitor
PembrolizumabKeytrudaPD1121 PR, median PFS 5.7 monthsBlay et al. Ann Oncol. 2019
3
Phase II TrialTargeted TherapyDasatinibSprycelPDGRF, c-KIT32median PFS 6.3 monthsSchuetze et al. Cancer 2016
4
Phase II TrialTargeted TherapySorafenibNexavarmultiple RTK271 PR, 73% SD (at 9 months)Bompas et al. Ann Oncol. 2015
5
Phase II TrialTargeted TherapyLapatinibTykerbEGFR1813 SDStacchiotti et al. Ann Oncol. 2013
6
Phase II TrialTargeted TherapyImatinibGleevecPDGFR501 PR, 70% SD, median PFS 9.2 monthsStacchiotti et al. Journal of Clinical Oncology, 2012
7
Phase II TrialTargeted TherapyImatinib + everolimusGleevec + AfinitorPDGFR + mTOR431 PR, 86% SDStacchiotti et al. Cancer, 2018
8
Phase II TrialTargeted TherapySunitinibSutentmultiple RTK94 SDGeorge et al. J Clin Oncol. 2009
9
Phase II TrialCytotoxic TherapyRubitecanOrathecinN/A151 PRChugh et al. J Clin Oncol. 2005
10
11
Phase I TrialTargeted Therapy + RadiationNilotinibTasignaPDGFR23median PFS 58.15 monthsCote et al. 2018
12
Phase I TrialTargeted TherapyTazemetostatTazverikEZH221 CR, 1 PRChi et al. 2017 (Abstract)
13
Phase I TrialTherapeutic VaccineGI-6301TarmogenBrachyury10median PFS 8.3 monthsHeery et al. Cancer Immunol Res. 2015
14
Phase I TrialTargeted Therapy + Cytotoxic TherapyImatinib mesyate + metronomic cyclophosphamideGleevec + CytoxanPDGFR7median PFS 10.2 monthsAdenis et al. British Journal of Cancer, 2013
15
16
Case SeriesTargeted TherapyPazopanib + SunitinibVotrient + Sutentmultiple RTK5median PFS 8.5 monthsLipplaa et al. Clin Sarcoma Res 2016
17
Case SeriesTargeted TherapyImatinibGleevecPDGFR4634 SDHindi et al. Euro J Cancer 2015
18
Case SeriesTargeted TherapyImatinibGleevecPDGFR22 SDRohatgi et al. Eurasian J Med 2015
19
Case SeriesTargeted TherapyErlotinib + BevacizumabTarceva + AvastinEGFR, VEGF33 SDAsklund et. al. Acta Oncol. 2014 Jan
20
Case SeriesTargeted TherapyImatinibGleevecPDGFR171 SDFerraresi et al. BMC Cancer. 2010
21
22
Case SeriesTargeted TherapyImatinib + SirolimusGleevec + RapamunePDGFR + mTOR98 SDStacchiotti et al. Ann Oncol. 2009
23
Case SeriesTargeted TherapyImatinibGleevecPDGFR64 symptomatic improvementCasali et al. Cancer 2004
24
25
Case ReportTargeted TherapyPazopanib VotrientVEGFR/PDGFR11 SDRibeiro et al. Case Rep Oncol Med. 2018
26
Case Report
Immune Checkpoint Inhibitor
NivolumabOpdivoPD111 PRMigliorini et al. OncoImmunology 2017
27
Case Report
Immune Checkpoint Inhibitor
PembrolizumabKeytrudaPD111 PRMigliorini et al. OncoImmunology 2017
28
Case ReportTherapeutic VaccineMVX-ONCO-1N/A11 PRMigliorini et al. OncoImmunology 2017
29
Case ReportTargeted TherapyErlotinib + LinsitinibTarceva + LinsitinibEGFR + IGF1R11 PRAleksic et al. Frontiers in Oncology 2017
30
Case ReportTargeted TherapyErlotinibTarcevaEGFR11 PRHouessinon et al. Case Reports Oncol. 2015
31
Case ReportCytoxoic TherapyVincristine + clophosphamide +doxorubicin + etoposide + ifosfamide11 CR (durable for 3+ years)Al-Rahawan MM et al. Pediatr Blood Cancer 2012
32
Case ReportTargeted TherapyThalidomideThalomide11 PRChay et al. J Clin Oncol. 2011
33
Case ReportTargeted TherapyCetuximab + GefitinibErbitux + IressaEGFR11 PRLinden et al. Acta Oncol. 2009
34
Case ReportTargeted TherapyErlotinibTarcevaEGFR11 PRSinghal et al. Anticancer Drugs. 2009
35
Case ReportTargeted TherapyCetuximab + GefitinibErbitux + IressaEGFR11 PRHof et al. Onkologie. 2006
36
Case ReportTargeted Therapy + Cytotoxic TherapyThalidomide + liposomal doxorubicinThalomid + Doxil11 SDSchönegger et al. Anticancer Drugs. 2005
37
Case ReportCytotoxic TherapyIfosfamide + doxorubicin11 PRScimeca eta al. J Pediatr Hematol Oncol. 1996
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...